Bio-Techne (BSP:T1CH34) Cyclically Adjusted Revenue per Share: R$1.20 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:T1CH34 Bio-Techne Corp BSP:T1CH34
79 GF Score
Price R$12.38
GF Value R$12.15
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Bio-Techne Cyclically Adjusted Revenue per Share?

Bio-Techne BSP:T1CH34 79 Cyclically Adjusted Revenue per Share is R$1.20 as of Jun. 2026. GuruFocus rates BSP:T1CH34 with a GF Score™ of 79/100 and a GF Value™ of R$12.15 (Fairly Valued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Bio-Techne's adjusted revenue per share for the three months ended in Jun. 2026 was R$0.349. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is R$1.20 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Bio-Techne's average Cyclically Adjusted Revenue Growth Rate was 8.60% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 9.30% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 11.50% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 12.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Bio-Techne was 15.80% per year. The lowest was 8.60% per year. And the median was 11.10% per year.

As of today (2026-08-25), Bio-Techne's current stock price is R$12.38. Bio-Techne's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was R$1.20. Bio-Techne's Cyclically Adjusted PS Ratio of today is 10.32.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Bio-Techne was 34.02. The lowest was 6.37. And the median was 14.03.


Bio-Techne  (BSP:T1CH34) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Bio-Techne's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=12.38/1.20
=10.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Bio-Techne was 34.02. The lowest was 6.37. And the median was 14.03.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Bio-Techne Cyclically Adjusted Revenue per Share Related Terms


Bio-Techne Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Bio-Techne's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bio-Techne Cyclically Adjusted Revenue per Share Chart

Bio-Techne Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.84 0.79 1.10 1.13 1.20

Bio-Techne Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.13 1.07 1.21 1.18 1.20

BSP:T1CH34 vs CYTK, SMMT, BMRN: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Bio-Techne's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bio-Techne Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bio-Techne's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Bio-Techne's Cyclically Adjusted PS Ratio falls into.


BSP:T1CH34
79GF Score
Bio-Techne Corp BSP:T1CH34
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bio-Techne Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Bio-Techne's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.349/333.9520*333.9520
=0.349

Current CPI (Jun. 2026) = 333.9520.

Bio-Techne Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.094 241.428 0.130
201612 0.098 241.432 0.136
201703 0.100 243.801 0.137
201706 0.115 244.955 0.157
201709 0.100 246.819 0.135
201712 0.112 246.524 0.152
201803 0.117 249.554 0.157
201806 0.147 251.989 0.195
201809 0.144 252.439 0.190
201812 0.146 251.233 0.194
201903 0.152 254.202 0.200
201906 0.157 256.143 0.205
201909 0.160 256.759 0.208
201912 0.160 256.974 0.208
202003 0.201 258.115 0.260
202006 0.192 257.797 0.249
202009 0.230 260.280 0.295
202012 0.239 260.474 0.306
202103 0.281 264.877 0.354
202106 0.265 271.696 0.326
202109 0.275 274.310 0.335
202112 0.308 278.802 0.369
202203 0.294 287.504 0.341
202206 0.296 296.311 0.334
202209 0.291 296.808 0.327
202212 0.294 296.797 0.331
202303 0.316 301.836 0.350
202306 0.301 305.109 0.329
202309 0.282 307.789 0.306
202312 0.278 306.746 0.303
202403 0.314 312.332 0.336
202406 0.342 314.175 0.364
202409 0.332 315.301 0.352
202412 0.376 315.605 0.398
202503 0.382 319.799 0.399
202506 0.373 322.561 0.386
202509 0.328 324.800 0.337
202512 0.343 324.054 0.353
202603 0.345 330.213 0.349
202606 0.349 333.952 0.349

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of R$1.20 mean?
Bio-Techne (BSP:T1CH34) has a Cyclically Adjusted Revenue per Share of R$1.20 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Bio-Techne and its competitors.
Is Bio-Techne's Cyclically Adjusted Revenue per Share too high?
Bio-Techne's current Cyclically Adjusted Revenue per Share is R$1.20. Overall, Bio-Techne has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bio-Techne's Cyclically Adjusted Revenue per Share compare to CYTK and SMMT?
Bio-Techne's Cyclically Adjusted Revenue per Share of R$1.20 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Bio-Techne and its competitors. Bio-Techne's current Cyclically Adjusted Revenue per Share is R$1.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Techne stock overvalued right now?
Based on GuruFocus' analysis, Bio-Techne (BSP:T1CH34) is currently considered Fairly Valued. The stock's GF Value™ is R$12.15, compared to a current price of R$12.38 — trading 1.9% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is R$1.20. Bio-Techne's overall GF Score™ is 79/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Bio-Techne (BSP:T1CH34), the current Cyclically Adjusted Revenue per Share is R$1.20 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bio-Techne (BSP:T1CH34) Overvalued in 2026?

Based on GuruFocus' analysis, Bio-Techne stock appears to be overvalued. The current stock price of R$12.38 is trading 1.9% above its estimated GF Value™ of R$12.15. GuruFocus considers Bio-Techne to be Fairly Valued.

Key valuation signals for BSP:T1CH34:

  • Cyclically Adjusted Revenue per Share: R$1.20
  • GF Value™: R$12.15 vs. price of R$12.38 (1.9% above fair value)
  • GF Score™: 79/100 with 7 warning signs

No single metric tells the full story. See the BSP:T1CH34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bio-Techne Business Description

Other Exchanges TECH:USATE1:Germany
Address 614 McKinley Place N.E., Minneapolis, MN, USA, 55413
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
79GF Score

Get the complete analysis for BSP:T1CH34

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$12.38
Price
R$12.15
GF Value